Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2018-05-14 Environmental & Social …
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
CORPORATE SOCIAL RESPONSIBILITY REPORT 2017
Environmental & Social Information Classification · 95% confidence The document is titled 'Corporate Social Responsibility Report 2017' and contains detailed sections on environmental protection, social responsibility management, corporate governance, stakeholder engagement, and community investment. It references the Environmental, Social and Governance Reporting Guideline issued by the Hong Kong Stock Exchange and covers the reporting period of the full year 2017. The content focuses on the company's ESG efforts, sustainability, and social responsibility rather than financial performance or audit results. It is not an annual report, earnings release, or regulatory filing. Given the emphasis on environmental, social, and governance factors, this document fits the category of Environmental & Social Information (SR). The document length and detail confirm it is a full report, not just an announcement or summary.
2018-05-14 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited first quarterly results for the three months ended 31 March 2018. It does not contain the actual financial results or detailed financial data, but merely announces the upcoming board meeting where such results will be approved. The document length is only 1280 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, announcements about board meetings or dates for approval of quarterly results fall under Regulatory Filings (RNS) as they do not contain substantive financial data or the report itself. Therefore, the correct classification is Regulatory Filings (RNS).
2018-05-14 English
VOLUNTARY ANNOUNCEMENT - "Q101-PEGYLATED RECOMBINANT HUMAN INTERFERON-alpha2a FOR INJECTION" FOR THE TREATMENT OF HEPATITIS WAS GRANTED CLINICAL TRIAL APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new pharmaceutical product. It is an announcement of a regulatory milestone rather than a financial report or detailed management discussion. The document is relatively short (2820 characters) and does not contain financial data, earnings information, or detailed report content. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications, nor is it a governance or board change announcement. The content is a corporate announcement about a product development milestone, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-05-10 English
VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF "DOXOFYLLINE GLUCOSE FOR INJECTION" AND "DOXOFYLLINE SODIUM CHLORIDE FOR INJECTION"
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of two pharmaceutical products. It is an announcement of a regulatory approval event, not a financial report, earnings release, or management discussion. The document is relatively short (2988 characters) and does not contain financial data, detailed analysis, or meeting materials. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category, as it informs the market about a significant business development without fitting into more specific categories like earnings, capital updates, or management changes. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2018-05-10 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/04/2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities movements rather than financial performance, management commentary, or regulatory certifications. It is a periodic regulatory filing reporting share capital movements, typical of a capital or share issue update. The document is lengthy (over 14,000 characters) and contains detailed data on share capital changes, not just an announcement or a brief summary. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA).
2018-05-03 English
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 25 MAY 2018 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF)
AGM Information Classification · 95% confidence The document is a proxy form for the Annual General Meeting (AGM) of CSPC Pharmaceutical Group Limited, scheduled for 25 May 2018. It includes instructions for shareholders to appoint proxies and vote on various resolutions such as receiving audited financial statements, dividend declaration, re-election of directors, appointment of auditors, and granting mandates related to share buy-back and issuance. The content is procedural and related to the AGM meeting arrangements and voting, not the actual AGM presentation materials or the full annual report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms and voting instructions.
2018-04-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.